Thèse numérisée par la Division de la gestion de documents et des archives de l'Université de Montréal.

L'utilisation de matériaux polymères a su s'imposer au cours du 20ième siècle, en remplaçant ou se combinant aux matériaux métalliques, pour des applications mécaniques toujours plus techniques. La grande diversité des propriétés physiques des polymères est intimement lié à leur forte complexité microstructurale, qui malgré leur utilisation massive reste, au demeurant, encore très incomprise. Afin de mieux comprendre les évolutions microstructurales aux échelles nano et micrométrique dont résultent le comportement macroscopique il est nécessaire de développer de nouvelles techniques de caractérisation in situ. Ce travail fait état de l'utilisation de la spectroscopie Raman couplée au système VidéoTractionTM afin d'obtenir des informations microstructurales de la déformation de polymère semi-cristallins. Pour cela, des polypropylènes de formulations diverses ont été étudiés, permettant de souligner le rôle joué par la matrice et les charges organiques et minérales dans le processus de déformation plastique. Des mesures in situ de l'orientation des chaînes macromoléculaires déterminées in situ par Raman ont été confirmées, au synchrotron Petra III d'Hambourg, par une expérience couplant le système VidéoTractionTM-Raman à un dispositif de diffusion des rayons X aux grands angles. L'endommagent volumique des matériaux a été étudié post mortem par Tomographie X et radiographie X. Les améliorations apportées au système VidéoTractionTM-Raman ainsi qu'une étude de la diffusion de la lumière incohérente de nos matériaux au cours de leurs déformations ont permis l'établissement d'un critère de mesure de l'endommagement volumique in situ par Raman / The use of polymer materials - replacing or combining with metallic materials - has successfully established itself in the 20th century for increasingly technical mechanical applications. The great diversity of polymers physical properties is closely related to their high microstructural complexity, which is still very misunderstood despite their massive use. The development of new techniques for in situ characterization allows to better understand the microstructural evolutions on nanoscale and micrometer scale which affect the macroscopic behavior. This work report the use of Raman spectroscopy coupled with the VideoTractionTM system in order to obtain information about the microstructural deformation of polymer. Various formulations of polypropylene were studied to highlight the role played by the polypropylene matrix and the organic and mineral fillers in the plastic deformation process. The in situ measures of the macromolecular chains' orientation determined by Raman were confirmed by the performing of an experimental setup coupling the Raman-VideoTractionTM system with a device of Wide angle X-ray scattering. The volume damage of material was studied post mortem using X-ray tomography. The improvements made to VideoTractionTM-Raman system and a study of the incoherent light scattering of our materials enabled the setting of a Raman criterion for measuring in situ the volume damage. The studies carried out to evaluate in situ macromolecular orientation and volume damage highlight the existence of competition between these two processes. The degree of influence of organic and mineral fillers in this competition within the polypropylene matrix was determined

Existing methods for pathogen/pollutant detection or wound infection monitoring employ high-cost instruments that could only be operated by trained personnel, and costly device-based detection requires a time-consuming field-to-lab process. This expensive process with multiple prerequisites prolongs the time that patients must wait for a diagnosis. Therefore, improved methods for point-of-care biosensing are necessary. In this study, we aimed to develop a direct, easy-to-use, portable, low cost, highly sensitive and selective sensor platform with the goal of pollutant detection and wound infection/cancer migration monitoring. This study has two main parts, including microfluidic, electrical, and optical sensing platforms. The first part, including chapters 2, 3, and 4, focuses on Bisphenol A (BPA) lateral flow assay (LFA) detection; the second part, including chapter 5 focuses on the electrical sensing platform fabrication for one of the markers of inflammation, matrix metalloproteinases-9 (MMP-9), monitoring/detection. In chapters 2, 3, and 4, we found that the few lateral flow assays (LFAs) established for detecting the endocrine-disrupting chemical BPA have employed citrate-stabilized gold nanoparticles (GNPs), which have inevitable limitations and instability issues. To address these limitations, in chapter 2, a more stable and more sensitive biosensor is developed by designing strategies for modifying the surfaces of GNPs with polyethylene glycol and then testing their effectiveness and sensitivity toward BPA in an LFA. In chapter 3, we describe the development of a new range-extended bisphenol A (BPA) detection method that uses a surface enhanced Raman scattering lateral flow assay (SERS-LFA) binary system. In chapter 4, we examine advanced bisphenol A (BPA) lateral flow assays (LFAs) that use multiple nanosystems. The assays include three nanosystems, namely, gold nanostars, gold nanocubes, and gold nanorods, which are rarely applied in LFAs, compared with general gold nanoparticles. The developed LFAs show different performances in the detection of BPA. In chapter 5, a stable electrical sensing platform is developed for MMP-9 detection.

Connor O’Hara July 29, 2019 Inhibition of Cancer Stem Cells by Glycosaminoglycan Mimetics In the United States cancer is the second leading cause of death, with colorectal cancer (CRC) being the third deadliest cancer and expected to cause over 51,000 fatalities in 2019 alone.1 The current standard of care for CRC depends largely on the staging, location, and presence of metastasis.2 As the tumor grows and invades nearby lymph tissue and blood vessels, CRC has the opportunity to invade not only nearby tissue but also metastasize into the liver and lung (most commonly).3 The 5-year survival rate for metastasized CRC is <15%, and standard of care chemotherapy regimens utilizing combination treatments only marginally improve survival.3-5 Additionally, patients who have gone into remission from late-stage CRC have a high risk of recurrence despite advances in treatment.6-7 The Cancer Stem-like Cell (CSC) paradigm has grown over the last 20 years to become a unifying hypothesis to support the growth and relapse of tumors previously regressed from chemotherapy (Figure 1).8 The paradigm emphasizes the heterogeneity of a tumor and its microenvironment, proposing that a small subset of cells in the tumor are the source of tumorigenesis with features akin to normal stem cells.9 The CSCs normally in a quiescent state survive this chemotherapy and “seed” tumor redevelopment.10 First observed in acute myeloid lymphoma models, CSCs have since been identified in various other cancers (to include CRC) by their cell surface antigens and unique properties characterizing them from normal cancer cells.11-12 These include tumor initiation, limitless self-renewal capacity to generate clonal daughter cells, as well as phenotypically diverse, mature, and highly differentiated progeny.13-14 Previously our lab has identified a novel molecule called G2.2 (Figure 2) from a unique library of sulfated compounds showing selective and potent inhibition of colorectal CSCs in-vitro.15 G2.2 is a mimetic of glycosaminoglycans (GAGs) and belongs to a class of molecules called non-saccharide GAG mimetics (NSGMs). Using a novel dual-screening platform, comparisons were made on the potency of G2.2 in bulk monolayer cells, primary 3D tumor spheroids of the same cell line, and subsequent generations of tumor spheroids. This work has shown in-vitro the fold-enhancement of CSCs when culturing as 3D tumor spheroids. Spheroid culture serves as a more accurate model for the physiological conditions of a tumor, as well as the functional importance of upregulating CSCs. Evaluation of G2.2 and other NSGMs was performed in only a few cell lines, developing a need to better understand the ability of G2.2 to inhibit spheroids from a more diverse panel of cancer cells to better understand G2.2’s mechanism. The last few decades have seen the advancement in fundamental biological and biochemical knowledge of tumor cell biology and genetics.16 CRC, in particular, has served as a useful preclinical model in recapitulating patient tumor heterogeneity in-vitro.17 Recent work has characterized the molecular phenotypes of CRC cell lines in a multi-omics analysis, stratifying them into 4 clinically robust and relevant consensus molecular subtypes (CMS).18-19 Our work was directed to screen a panel of cells from each of the molecular subtypes and characterize the action of G2.2 and 2nd generation lipid-modified analogs, synthesized to improve the pharmacokinetic properties of the parent compound. Four NSGMs, namely G2.2, G2C, G5C, and G8C (Figure 2) were studied for their ability to inhibit the growth of primary spheroids across a phenotypically diverse panel. Compound HT-29 IC50 (μM) Panel Average IC50 (μM) G2.2 28 ± 1 185 ± 55 G2C 5 ± 2 16 ± 15 G5C 8 ± 2 63 ± 19 G8C 0.7 ± 0.2 6 ± 3 Primary spheroid inhibition assays were performed comparing the potency of new NSGMs to G2.2. Fifteen cell lines were evaluated in a panel of colorectal adenocarcinoma cell lines with several cell lines representing each CMS. Primary spheroid inhibition assays revealed 3 distinct response with regard to G2.2’s ability to inhibit spheroid growth. Cells from CMS 3 and 4, which display poor clinical prognosis, metabolic dysregulation, and enhanced activation of CSC pathways, showed the most sensitivity to G2.2 (mean IC50 = 89 ± 55 μM). Mesenchymal CMS 4 cell lines were over 3-fold more sensitive to treatment with G2.2 when compared to CMS 1 cell lines. Resistant cell lines were composed entirely of CMS 1 and 2 (mean IC50 = 267 ± 105 μM). In contrast, all lipid-modified analogs showed greater potency than the parent NSGM in almost every CRC cell line. Of the three analogs, G8C showed the greatest potency with a mean IC50 of less than 15 μM. Of the CRC spheroids studied, HT-29 (CMS 3) was most sensitive to G8C (IC50 = 0.73 μM). To evaluate the selectivity of NSGMs for CSC spheroid inhibition, MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium) cytotoxicity assays were performed on monolayer cell culture, and the fold-selectivity of NSGM for spheroids was analyzed. Data shows that NSGMs preferentially target CSC-rich spheroids compared with monolayer cellular growth, with G2.2 having over 7-fold selectivity for spheroid conditions. This fold selectivity was enhanced in CMS 3/4, supporting the idea that G2.2 targets a mesenchymal and stem-like phenotype. To further validate this selectivity, limiting dilution assays were performed across the panel to determine the tumor-initiating capacity of each cell line. Cell lines which showed a sensitive response to G2.2 were over 2-fold more likely to develop into spheroids, validating the previous hypothesis. Further characterization was performed analyzing the changes G2.2 induced on CSC markers, as well as the basal expression of a unique pair of cancer cells. Western blots showed a reduction in self-renewal marker across all CMS after treatment with G2.2, and that cell lines sensitive to G2.2-treatment overexpress mesenchymal and stem-like markers. G2.2-resistant cell lines show an epithelial phenotype, lacking this expression. The positive results observed in these studies enhance the understanding of G2.2 and analogs, and further evaluation with additional cell lines of various tissues would improve the knowledge thus far gained. However, all experiments described take valuable time to perform and analyze. Thus, there became a need to develop a high-throughput screening (HTS) platform for our assays that standardized analysis and enhanced productivity. Initial development of the method for this assay are underway, and recent evidence from these evaluations of breast cancer spheroids suggests that G2.2 and analogs may be tissue-specific compounds for the treatment of cancer. Future work entails refining the application of this method for evaluation of the NCI-60 (National Cancer Institute) tumor cell panel. Overall, these results make several suggestions concerning the NSGMs evaluated against the panel. First, G2.2 selectively targets CSCs with limited toxicity to monolayer cells of the same cell line. Further, G2.2 has the greatest potency with CMS 3/4, whose mesenchymal phenotypes are associated with poor clinical prognosis and enrichment of CSCs. Supporting evidence include that sensitive cell lines are highly tumorigenic and show enhanced expression of mesenchymal/CSC markers compared to resistant cell lines. Lipid-modification of G2.2 enhances in-vitro potency against spheroid growth, with nM potency reached in the most sensitive cell lines. Evidence in the development of a HTS platform also suggests these NSGMs show tissue specificity to cancers of the intestine. Further work characterizing the mechanism of NSGMs in a broader multi-tissue panel will enhance our understanding of the compounds as a potential therapy to dramatically improve patient survival through specific targeting of tumorigenesis. References 1. Colorectal Cancer Facts & Figures 2017-2019. American Cancer Society 2017. 2. Compton, C. C.; Byrd, D. R.; Garcia-Aguilar, J.; Kurtzman, S. H.; Olawaiye, A.; Washington, M. K. Colon and rectum. In AJCC Cancer Staging Atlas, 2nd ed.; Ed. Springer Science: New York, 2012; pp 185–201. 3. Van Cutsem, E.; Cervantes, A.; Adam, R.; Sobrero, A.; Van Krieken, J. H.; Aderka, D.; Aranda Aguilar, E.; Bardelli, A.; Benson, A.; Bodoky, G.; et al. ESMO consensus guidelines for the management of patients with metastatic colorectal cancer. Ann. Oncol. 2016, 27, 1386–422. 4. Siegel, R. L.; Miller, K. D.; Fedewa, S. A.; Ahnen, D. J.; Meester, R. G. S.; Barzi, A.; Jemal, A. Colorectal cancer statistics, 2017. CA Cancer J. Clin. 2017, 67, 177–193. 5. Moriarity, A.; O'Sullivan, J.; Kennedy, J.; Mehigan, B.; McCormick, P. Current targeted therapies in the treatment of advanced colorectal cancer: a review. Ther. Adv. Med. Oncol. 2016, 8, 276–293. 6. Seidel, J.; Farber, E.; Baumbach, R.; Cordruwisch, W.; Bohmler, U.; Feyerabend, B.; Faiss, S. Complication and local recurrence rate after endoscopic resection of large high-risk colorectal adenomas of >/=3 cm in size. Int. J. Colorectal Dis. 2016, 31, 603–611. 7. Pugh, S. A.; Shinkins, B.; Fuller, A.; Mellor, J.; Mant, D.; Primrose, J. N. Site and stage of colorectal cancer influence the likelihood and distribution of disease recurrence and postrecurrence survival: data from the FACS randomized controlled trial. Ann. Surg. 2016, 263, 1143–1147. 8. Batlle, E.; Clevers, H. Cancer stem cells revisited. Nat. Med. 2017, 23, 1124–1134. 9. Hanahan, D.; Weinberg, R. A. Hallmarks of cancer: the next generation. Cell 2011, 144, 646–674. 10. Tirino, V.; Desiderio, V.; Paino, F.; De Rosa, A.; Papaccio, F.; La Noce, M.; Laino, L.; De Francesco, F.; Papaccio, G. Cancer stem cells in solid tumors: an overview and new approaches for their isolation and characterization. FASEB J. 2013, 27, 13–24. 11. Bonnet, D.; Dick, J. E. Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell. Nat. Med. 1997, 3, 730–737. 12. Desai, A.; Yan, Y.; Gerson, S. L. Concise reviews: cancer stem cell targeted therapies: toward clinical success. Stem Cells Transl. Med. 2019, 8, 75–81. 13. Munro, M. J.; Wickremesekera, S. K.; Peng, L.; Tan, S. T.; Itinteang, T. Cancer stem cells in colorectal cancer: a review. J. Clin. Pathol. 2018, 71, 110–116. 14. Zhou, Y.; Xia, L.; Wang, H.; Oyang, L.; Su, M.; Liu, Q.; Lin, J.; Tan, S.; Tian, Y.; Liao, Q.; Cao, D. Cancer stem cells in progression of colorectal cancer. Oncotarget 2018, 9, 33403–33415. 15. Patel, N. J.; Karuturi, R.; Al-Horani, R. A.; Baranwal, S.; Patel, J.; Desai, U. R.; Patel, B. B. Synthetic, non-saccharide, glycosaminoglycan mimetics selectively target colon cancer stem cells. ACS Chem. Biol. 2014, 9, 1826–1833. 16. Punt, C. J.; Koopman, M.; Vermeulen, L. From tumour heterogeneity to advances in precision treatment of colorectal cancer. Nat. Rev. Clin. Oncol. 2017, 14, 235–246. 17. Mouradov, D.; Sloggett, C.; Jorissen, R. N.; Love, C. G.; Li, S.; Burgess, A. W.; Arango, D.; Strausberg, R. L.; Buchanan, D.; Wormald, S.; et al. Colorectal cancer cell lines are representative models of the main molecular subtypes of primary cancer. Cancer Res. 2014, 74, 3238–3247. 18. Guinney, J.; Dienstmann, R.; Wang, X.; de Reynies, A.; Schlicker, A.; Soneson, C.; Marisa, L.; Roepman, P.; Nyamundanda, G.; Angelino, P.; et al. The consensus molecular subtypes of colorectal cancer. Nat. Med. 2015, 21, 1350–1356. 19. Berg, K. C. G.; Eide, P. W.; Eilertsen, I. A.; Johannessen, B.; Bruun, J.; Danielsen, S. A.; Bjornslett, M.; Meza-Zepeda, L. A.; Eknaes, M.; Lind, G. E.; et al. Multi-omics of 34 colorectal cancer cell lines - a resource for biomedical studies. Mol. Cancer 2017, 16, 116–132.

Se realizó el estudio de las propiedades térmicas y mecánicas de mezclas de Poli(Etilén Tereftalato) (PET) con resinas poliméricas basadas enl Bisfenol-A: Poli(Carbonato de Bisfenol-A) (PC) y Poli(Hidroxi-Éter de Bisfenil-A) (PHEB), en contenidos no superiores a un 30% en peso de estos polímeros y preparadas por extrusión doble-husillo.Una evaluación físico-química (ft-IR, densidad y MVR) de ambos sistemas indicó que pueden ocurrir reacciones de transesterificación, principalmente entre el PET y el PC y verificado vía DSC y DMTA, mientras que dichas reacciones tienen una baja extensión en el caso del PHEB, principalmente evidenciado en la pérdida de la capacidad de cristalización del PET (sin mayores cambios en su transición vítrea) en presencia de PC y casi invariabilidad al adicionar PHEB. Con el apoyo de SEM se verificó la presencia de fases ricas de ambos componentes en las mezclas en todo el rango de composiciones, verificándose el carácter inmiscible de ambos sistemas.A través de un fraccionamiento térmico por Autonucleaciones y Recocidos Sucesivos (SSA) y medidas del MVR, ensayos que favorecieron la transesterificación, se estableció que ésta promueve un aumento de la masa molecular en ambos sistemas, donde en las mezclas PET/PC esto se da por reacciones de extensión de cadena y que en las mezclas PET/PHEB conducen a la formación de ramificaciones largas y entrecruzamientos.Las propiedades mecánicas a tracción y flexión indicaron un aumento de la resistencia mecánica y deformabilidad a mayor contenido de fase bisfenólica, al observarse un aumento de los parámetros característicos de estos ensayos, donde módulos elásticos y tensiones siguieron generalmente una desviación positiva de la "Ley Aditiva de Mezcla" (LAM). Tales tendencias indicaron un efecto rigidizante de la fase bisfenólica combinado con interacciones fuertes entre los componentes que favoreció la transmisión de tensiones y la deformabilidad de la mezcla, existiendo una compatibilidad mecánica aceptable al menos a bajas velocidades de deformación, principalmente en las mezclas PET/PC en donde hay evidencias de un aumento en la tenacidad. Se verificó que hay mejoras en la Resistencia al Impacto tanto caída de dardo como pendular al menos hasta un 20% de PC, superando a las mezclas PET/PHEB las cuales manifestaron una fuerte sensibilidad a la entalla.En el análisis de la fractura a través de la Mecánica de la Fractura Elástico Lineal (LEFM) a altas velocidades y el Trabajo Esencial de Fractura (EWF) a bajas velocidades de solicitación, para contenido no superiores a 10% de fase PC y PHEB donde la morfología de fases fue comparable (partículas), se tiene que los parámetros de fractura fueron siempre superiores para las mezclas PET/PC, con una tendencia general de que el PC aporta mejoras a estos parámetros respecto al PET, mientras que el PHEB no los afecta o tiende a disminuirlos. Esto sugiere que que la adhesión interfacial es un factor determinante que favorece la transmisión de tensiones, particularmente favorable en las mezclas PET/PC por su mayor reactividad.A mayores contenidos de fase bisfenólica, el comportamiento es más complejo como consecuencia del particular balance entre tamaño, geometría y orientación de la fase dispersa que tiende a dominar sobre la adhesión interfacial, detectándose procesos de cavitación en la mayoría de las condiciones de ensayos que promovieron pocas mejoras o decaimiento en los parámetros de fractura respecto al PET. Cabe destacar que los parámetros de fractura LEFM indicaron que todos los materiales presentaron una fractura en condiciones mixtas con una componente importante de tensión plana, con excepción de las mezclas PET/PHEB que corresponderían a condiciones de deformación plana, todo lo cual fue corroborado a través del análisis fractográfico.

La motivació per a la realització d'aquest projecte sorgeix de la problemàtica ambiental ja coneguda que existeix amb relació a la contaminació produïda pels reactius utilitzats en el blanqueig de pastes per a paper, i per l'interès en la utilització de matèries primes anuals, com per exemple els residus agrícoles.La present tesi forma part de les línies d'investigació en el blanqueig de pastes per a paper que es porten a terme en el laboratori de l'Especialitat Paperera i Gràfica del Departament d'Enginyeria Tèxtil i Paperera de la Universitat Politècnica de Catalunya, essent la primera tesi que es realitza en temes de blanqueig amb ozó i d'utilització d'enzims. Mitjançant els estudis realitzats s'arriba a obtenir una seqüència totalment lliure de clor (TCF) que inclou una etapa de blanqueig amb ozó (Z) i un tractament enzimàtic amb xilanasa (X), amb la qual s'aconsegueix obtenir una pasta blanquejada d'Eucalyptus amb propietats finals de les pastes, papers i efluents comparables amb les d'una seqüència ECF. Aquesta seqüència de blanqueig és també aplicable a una pasta de palla de blat, amb la qual s'obté bones propietats finals. Així doncs, el present treball d'investigació tracta bàsicament tres qüestions:La primera consisteix en l'increment de la selectivitat del blanqueig amb ozó per al qual es realitza un estudi de l'aplicació de diferents tractaments abans, durant i després d'aquest estadi. Els resultats obtinguts mostren que és convenient realitzar un postractament amb borohidrur sòdic ja que és molt eficient degut al seu elevat potencial reductor de grups carbonil, la qual cosa es corrobora amb l'estudi realitzat sobre el número de talls en la cadena cel·lulòsica (CS). Pel que fa als diferents pretractaments i additius aplicats, aquests últims són més beneficiosos, i en concret els que es realitzen a pH àcid, indicant que el pH té un efecte important en la selectivitat de l'etapa Z, cosa que es confirma amb els estudis cinètics realitzats, i que a més està relacionat amb la major formació de radicals hidroxil a pH alcalí. La naturalesa de l'additiu utilitzat a pH àcid també influeix en la selectivitat de l'etapa Z. Dels diferents additius estudiats i aplicats a pH entre 2 i 3, l'àcid oxàlic és el més eficient ja que presenta un efecte "addicional" a la resta d'additius diferent al pH, influint positivament en la cinètica de la etapa Z ja que augmenta la cinètica de deslignificació i disminueix la de degradació de la cel·lulosa. A través dels estudis realitzats es dedueix que aquest efecte addicional de l'àcid oxàlic és degut a un conjunt de factors: captador de radicals hidroxil, estabilitzador de l'ozó, disminució de l'inflament de la cel·lulosa, catalitzador de les reaccions de l'ozó i/o radicals amb la lignina, aportador d'hidrogen i quelant de cations metàl·lics. La dosi necessària d'àcid oxàlic és molt petita i inclús inferior a la quantitat que es forma en el propi estadi. Per tant, en cas de tancament de circuits, es podria realitzar una recirculació dels efluents dins de l'estadi Z, aprofitant el propi àcid oxàlic que es forma en aquesta etapa.La segona part està basada en l'estudi del pretractament enzimàtic amb xilanasa aplicat en una seqüència TCF de pasta d'Eucalyptus amb la qual cosa s'aconsegueix un efecte "estimulador" del blanqueig, ja que s'incrementa la facilitat de blanquejar en els posteriors estadis de blanqueig, cosa que permet una reducció del consum de reactius. Aquest efecte es relaciona amb l'eliminació de xilans i de grups hexenurònics que es confirma amb els estudis de microscopia electrònica d'escombrat (SEM) i de determinació d'hidrats de carboni per HPLC. Amb els estudis cinètics realitzats s'obté que amb el tractament X s'elimina una part de lignina que no s'aconsegueix eliminar durant el blanqueig amb ozó. El tercer tema es l'aplicació de la seqüència TCF obtinguda, en pasta de palla de blat, amb la modificació d'alguna de les condicions, obtenint resultats no tan favorables com amb l'Eucalyptus, però realment bons tractant-se d'una pasta de palla. Les tècniques d'anàlisi utilitzades -determinació d'hidrats de carboni mitjançant HPLC, observació de la superfície de la fibra utilitzant la microscopia electrònica d'escombrat (SEM) i de transmissió (TEM), determinació de cations metàl·lics per espectroscopia d'absorció atòmica, diferents tècniques per a la determinació de la cristal·linitat i el grau d'oxidació de les fibres, estudis cinètics de l'etapa de blanqueig amb ozó i determinació de grups hexenurònics per espectroscopia UV- han permès una major comprensió dels mecanismes de reacció que tenen lloc en la seqüència estudiada. Així doncs, estudiant l'efecte de l'àcid oxàlic s'aconsegueix saber quins són els requisits que ha de complir un additiu per a ser el més eficient possible en el blanqueig amb ozó.Finalment s'ha d'indicar que part d'aquests estudis s'han realitzat en el Centre Technique du Papier (CTP) de Grenoble (França) i en el Royal Institute of Technology (KTH) d'Estocolm (Suècia).

Les fructose-1,6-bisphosphate aldolases (FBPA) sont des enzymes glycolytiques (EC 4.1.2.13) qui catalysent la transformation réversible du fructose-1,6-bisphosphate (FBP) en deux trioses-phosphates, le glycéraldéhyde-3-phosphate (G3P) et le dihydroxyacétone phosphate (DHAP). Il existe deux classes de FBPA qui diffèrent au niveau de leur mécanisme catalytique. Les classes I passent par la formation d’un intermédiaire covalent de type iminium alors que les classes II, métallodépendantes, utilisent généralement un zinc catalytique. Contrairement au mécanisme des classes I qui a été très étudié, de nombreuses interrogations subsistent au sujet de celui des classes II. Nous avons donc entrepris une analyse détaillée de leur mécanisme réactionnel en nous basant principalement sur la résolution de structures cristallographiques. De nombreux complexes à haute résolution furent obtenus et ont permis de détailler le rôle de plusieurs résidus du site actif de l’enzyme. Nous avons ainsi corrigé l’identification du résidu responsable de l’abstraction du proton de l’O4 du FBP, une étape cruciale du mécanisme. Ce rôle, faussement attribué à l’Asp82 (chez Helicobacter pylori), est en fait rempli par l’His180, un des résidus coordonant le zinc. L’Asp82 n’en demeure pas moins essentiel car il oriente, active et stabilise les substrats. Enfin, notre étude met en évidence le caractère dynamique de notre enzyme dont la catalyse nécessite la relocalisation du zinc et de nombreux résidus. La dynamique de la protéine ne permet pas d’étudier tous les aspects du mécanisme uniquement par l’approche cristallographique. En particulier, le résidu effectuant le transfert stéréospécifique du proton pro(S) sur le carbone 3 (C3) du DHAP est situé sur une boucle qui n’est visible dans aucune de nos structures. Nous avons donc développé un protocole de dynamique moléculaire afin d’étudier sa dynamique. Validé par l’étude d’inhibiteurs de la classe I, l’application de notre protocole aux FBPA de classe II a confirmé l’identification du résidu responsable de cette abstraction chez Escherichia coli (Glu182) mais pointe vers un résidu diffèrent chez H. pylori (Glu149 au lieu de Glu142). Nos validations expérimentales confirment ces observations et seront consolidées dans le futur. Les FBPA de classe II sont absentes du protéome humain mais sont retrouvées chez de nombreux pathogènes, pouvant même s'y révéler essentielles. Elles apparaissent donc comme étant une cible idéale pour le développement de nouveaux agents anti-microbiens. L’obtention de nouveaux analogues des substrats pour ces enzymes a donc un double intérêt, obtenir de nouveaux outils d’étude du mécanisme mais aussi développer des molécules à visée pharmacologique. En collaboration avec un groupe de chimistes, nous avons optimisé le seul inhibiteur connu des FBPA de classe II. Les composés obtenus, à la fois plus spécifiques et plus puissants, permettent d’envisager une utilisation pharmacologique. En somme, c’est par l’utilisation de techniques complémentaires que de nouveaux détails moléculaires de la catalyse des FBPA de classe II ont pu être étudiés. Ces techniques permettront d’approfondir la compréhension fine du mécanisme catalytique de l’enzyme et offrent aussi de nouvelles perspectives thérapeutiques. / Fructose-1,6-bisphosphate aldolases (FBPA) are glycolytic enzymes (EC 4.1.2.13) that catalyze the reversible cleavage of fructose-1,6-bisphosphate (FBP) into the triose phosphates, glyceraldehyde-3-phosphate (G3P) and dihydroxyacetone phosphate (DHAP). There are two classes of FBPAs that differ at the level of their mechanism. Class I FBPAs form a covalent iminium intermediate whereas class II FBPAs, being metalloenzymes, generally use a catalytic zinc in their reaction mechanism. In contrast to the mechanism of the class I FBPAs, which has been thoroughly studied, there are several unresolved inquiries as to the mechanism of class II FBPAs. We have therefore pursued a detailed analysis of the reaction mechanism using as a primary tool the elucidation of crystallographic structures. Several high resolution complexes have been resolved and have provided critical evidence to help us suggest the implication and role of several key residues in the active site. Consequently, we have correctly identified the residue which is responsible for the abstraction of the O4 proton from FBP, a vital step in the reaction mechanism. The residue responsible for this abstraction, which had incorrectly been assigned to Asp82 (in Helicobacter pylori), has been appropriately consigned to His180, a residue which is involved in coordinating the zinc molecule. Nevertheless, Asp82 remains an important residue as it orients, activates and stabilizes substrates. Finally, our study brings to evidence the dynamic character of our enzyme in which catalysis entails the relocalization of the catalytic zinc and several residues. The complexity of this reaction, notably one of the proton exchanges in the mechanism, could not be resolved solely by crystallographic means. In fact, the residue responsible for the stereospecific transfer of the pro(S) proton on carbon 3 (C3) of DHAP is situated on a loop that was not resolved in any of our structures. We therefore developed a molecular dynamics approach to study this intricate movement. After preliminary validation by inhibitor studies with class I FBPAs, the protocol was applied to class II FBPAs and several remarkable observations emerged: the residue responsible for this abstraction in Escherichia coli is Glu182 whereas a different residue, Glu149 (instead of Glu142) appears to assume this role in H. pylori. Our preliminary validations have confirmed this observation and shall be further consolidated in the future. Class II FBP aldolases, although absent from the human proteome, are prevalently found in several pathogens, and have further been found to be essential to a number of these organisms. As such, they are ideal targets for the development of novel anti-microbial agents. Developing new analogues of the cognate substrates of these enzymes is therefore not only advantageous for mechanistic studies, but has endless pharmacological potential. In the context of a collaborative effort involving a group of chemists, a compound that initially had an inhibition constant in the millimolar range was optimized and produced a series of compounds that inhibit in the nanomolar range.

Thèse numérisée par la Division de la gestion de documents et des archives de l'Université de Montréal

No description available.

L'objectif principal de la thèse porte sur la synthèse contrôlée et la caractérisation d’architectures macromoléculaires complexes originales à base de POE. Les POEs α-undécènyle-ω-hydroxy sont obtenus par polymérisation anionique par ouverture de cycle de l’oxyde d’éthylène. Le groupement hydroxyle est modifié pour accéder à des POEs α-undécènyle-ω-méthacrylate et des POEs α-undécènyle-ω-acétylène. Ces premiers POEs sont ensuite utilisés pour préparer soit des POEs à structure en peigne par ATRP dans l'eau soit par l'intermédiaire de réaction « click », des POEs à structure en étoile tétrafonctionnelles, tandis qu’avec les seconds permettent d’obtenir des PI-b-POE par réaction « click » avec le polyisoprène ω-azoture. Les extrémités de chaîne de POE commerciaux α-méthoxy-ω-hydroxy sont modifiées en POEs α-méthoxy-ω-allyle ou en POEs α-méthoxy-ω-undécènyle pour synthétiser par réaction d’hydrosilylation des étoiles de POE à structures en étoile octafonctionnelles. / The main objective of the thesis focuses on the controlled synthesis and the characterization of original and complex macromolecular architectures based on PEO. α-Undecenyl-ω-hydroxy PEOs are obtained by anionic ring opening polymerization of ethylene oxide. The hydroxyl group is modified to access to α-undecenyl-ω-methacrylate PEOs and α-undecenyl-ω-acetylene PEOs. These first PEOs are used to prepare either comb-shaped PEOs by ATRP in water or through by click reaction of tetrafunctional star-shaped PEOs. Whereas the second PEOs allow obtaining block copolymers PI-b-PEO via click reaction with ω-azide polyisoprene. The chain-ends of commercial α-methoxy-ω-hydroxy PEO are modified in α-methoxy-ω-allyl PEOs or in α-methoxy-ω-undecenyl PEOs to synthesize by hydrosilylation reaction octafunctional star-shaped PEOs.